急性A型主动脉夹层手术中的肝素管理与凝血:一项随机对照试验
这项单中心、部分盲法随机对照试验将26例急性A型主动脉夹层急诊手术患者1:1分配至肝素剂量反应(HDR)组或活化凝血时间(ACT)指导抗凝组,主要终点为体外循环后肝素逆转时凝血酶原片段F1+2较基线的变化,两组间无显著差异,两种方案均未能充分抑制凝血酶生成。
要点
- 急性A型主动脉夹层患者基线存在显著消耗性凝血病,术中持续凝血酶生成。
核心结论
- 两种抗凝方案均未能充分抑制凝血酶生成,急性主动脉夹层术前消耗性凝血病加重凸显当前抗凝策略不足。
研究设计与样本
- 单中心、部分盲法随机对照试验,2022年12月至2024年9月共随机26例(HDR组14例,ACT组12例),按器官功能障碍和术前抗凝分层。
临床怎么用
- 当前HDR或ACT指导抗凝均不能充分抑制急性A型主动脉夹层手术中的凝血酶生成,需关注术前消耗性凝血病。
局限性
- 样本量小(26例),部分盲法设计,主要终点未达显著差异,敏感性分析样本为25例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute type A aortic dissection remains a life-threatening condition characterized by profound consumptive coagulopathy and perioperative transfusion requirements. The optimal anticoagulation strategy during cardiopulmonary bypass remains uncertain. OBJECTIVES: To assess baseline coagulation and compare the impact of 2 standard anticoagulation strategies on thrombin generation and clinical outcomes in patients undergoing emergent surgery for acute type A aortic dissection. METHODS: In this single-center, partially blinded, randomized controlled trial, patients were allocated 1:1 to heparin dose-response (HDR) or activated clotting time (ACT) guided anticoagulation. Randomization was stratified by organ dysfunction and preoperative anticoagulation. The primary endpoint was the change in prothrombin fragment 1+2 (F1+2) from baseline to heparin reversal after cardiopulmonary bypass. Secondary endpoints included coagulation markers, bleeding, transfusion, and clinical outcomes up to 90 days. RESULTS: Between December 2022 and September 2024, 26 patients were randomized (HDR = 14; ACT = 12). Both groups demonstrated marked baseline consumptive coagulopathy with ongoing intraoperative thrombin generation. Despite baseline differences in F1+2, the primary endpoint did not differ significantly (median change HDR: 333 [IQR 654] vs ACT: -92 pmol/L [IQR 1,984], P = .31). Post hoc baseline-adjusted ANCOVA sensitivity analysis of log-transformed change (n = 25) showed a 14% lower fold-increase in HDR compared with ACT (HDR/ACT ratio 0.86, 95% CI 0.63-1.17; P = .32). Secondary endpoints were comparable, except for a lower protamine-to-heparin ratio in the HDR group (0.51 vs 0.75; P < .001). CONCLUSION: Thrombin generation was insufficiently suppressed by either anticoagulation protocol. Exacerbation of preoperative consumptive coagulopathy highlights the insufficiency of current anticoagulation strategies in acute aortic dissection. CLINICAL TRIAL REGISTRY NUMBER: ClinicalTrials.gov: NCT05484830 (May 26, 2022).
引用
- Eschen JT, Larsen JB, Damsted AR, et al. Heparin management and coagulation in acute aortic dissection surgery: a randomized controlled trial. J Thromb Haemost. 2026. PMID: 42833295. doi:10.1016/j.jtha.2026.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。